Tafasitamab Combination Provides Prolonged, Durable Response

According to 5-year follow-up data, the combination of tafasitamab-cxix and lenalidomide produced a durable response in patients with diffuse large B-cell lymphoma.

Related Keywords

Orlando , Florida , United States , University Hospital , American , Tim Demuth , Steven Stein , Johannes Duell , American Association For Cancer Research , Morphosys Us Inc , American Association , Cancer Research , Annual Meeting , Medical Clinic ,